MammaPrint, BluePrint, and Full-genome Data Linked with Clinical
Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX)
The purpose of the FLEX Registry is to extract the full genomic information from the MammaPrint and BluePrint tumor samples utilizing a full genome microarray. The expanded gene expression data in FLEX Registry will be then be linked to clinical, pathological, treatment, and outcome data also collected in this registry. The FLEX Registry will curate a large-scale registry of gene expression data that is coupled with clinical data. This comprehensive database will support the identification of clinically relevant and/or scientifically interesting new gene associations in a population based setting, as well as the post-market validation of existing signatures.
Stage I-III male or female breast cancer patients who receive MammaPrint with or without BluePrint testing.
18 - 105
Healthy Volunteers Needed
Duration of Participation
10 years after definitive surgery
Dr. Jacqueline Vuky email: firstname.lastname@example.org